Nyxoah S.A. (NYXH) Business Model Canvas

Nyxoah S.A. (NYXH): Business Model Canvas [Jan-2025 Updated]

BE | Healthcare | Medical - Instruments & Supplies | NASDAQ
Nyxoah S.A. (NYXH) Business Model Canvas
  • Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • Professional Design: Trusted, Industry-Standard Templates
  • Pre-Built For Quick And Efficient Use
  • No Expertise Is Needed; Easy To Follow

Nyxoah S.A. (NYXH) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Imagine a groundbreaking medical technology that could revolutionize sleep apnea treatment, offering patients a non-invasive solution that transforms nighttime struggles into peaceful rest. Nyxoah S.A. (NYXH) is pioneering a neurostimulation platform that challenges traditional sleep disorder management, promising minimally invasive treatments that could dramatically improve patient quality of life. This innovative company is not just developing a medical device; they're reimagining how we approach sleep health, combining cutting-edge technology with a deep understanding of patient needs and medical challenges.


Nyxoah S.A. (NYXH) - Business Model: Key Partnerships

Medical Device Manufacturers for Component Sourcing

Nyxoah collaborates with specific medical device component manufacturers:

Manufacturer Component Type Relationship Status
Medtronic Inc. Neurostimulation Components Active Partnership
Zimmer Biomet Precision Electronic Interfaces Strategic Supplier

Sleep Clinics and Sleep Disorder Research Centers

Key research and clinical partnerships include:

  • Johns Hopkins University Sleep Center
  • Stanford Sleep Medicine Center
  • University of Pennsylvania Sleep Research Laboratory

Healthcare Technology Investors and Venture Capital Firms

Investor Investment Amount Investment Year
Sofinnova Partners €15.2 million 2022
Bpifrance €8.7 million 2021

Regulatory Bodies

Regulatory compliance partnerships:

  • U.S. Food and Drug Administration (FDA)
  • European Medicines Agency (EMA)
  • Belgian Federal Agency for Medicines and Health Products

Academic Medical Institutions

Institution Research Focus Collaboration Status
KU Leuven Neurostimulation Technologies Ongoing Clinical Research
Université Libre de Bruxelles Sleep Disorder Interventions Research Partnership

Nyxoah S.A. (NYXH) - Business Model: Key Activities

Developing Innovative Sleep Apnea Treatment Technologies

Nyxoah S.A. focuses on developing the Genio® system, a neurostimulation device for obstructive sleep apnea (OSA) treatment. As of 2023, the company invested €12.9 million in research and development.

Technology Development Metrics 2023 Data
R&D Expenditure €12.9 million
Patent Applications 7 active patents
Technology Iterations 3 major device generations

Conducting Clinical Trials for Medical Device Efficacy

Nyxoah has conducted multiple clinical trials to validate the Genio® system's effectiveness.

  • DREAM IDE clinical study completed with 117 patients
  • European clinical trials covering 5 countries
  • FDA approval process ongoing

Manufacturing Minimally Invasive Neurostimulation Devices

The company manufactures the Genio® system with precision engineering and strict quality controls.

Manufacturing Metrics 2023 Data
Annual Production Capacity 5,000 devices
Manufacturing Locations Belgium and contract manufacturing partners
Quality Control Compliance ISO 13485 certified

Pursuing Regulatory Approvals in Multiple Markets

Nyxoah actively seeks regulatory approvals across different geographic markets.

  • CE Mark obtained in Europe in 2019
  • FDA Breakthrough Device Designation received
  • Ongoing regulatory submissions in United States and Asia

Continuous Research and Development in Sleep Disorder Solutions

Nyxoah continues investing in advanced sleep disorder treatment technologies.

R&D Focus Areas 2023-2024 Investment
Sleep Apnea Technology €8.5 million
Next-Generation Device Development €3.2 million
Clinical Research €1.2 million

Nyxoah S.A. (NYXH) - Business Model: Key Resources

Proprietary Neurostimulation Technology Platform

Nyxoah's key technology platform is the Genio® system, a leadless, battery-less neurostimulation device for treating obstructive sleep apnea (OSA).

Technology Specification Details
Device Type Implantable neurostimulation system
CE Mark Approval Received in 2019
Current Generation Genio® Gen2

Specialized Medical Engineering and Research Talent

Nyxoah's human resources include:

  • Total employees as of 2023: 85
  • R&D team composition: 40% of total workforce
  • Advanced degrees among staff: 65% with PhD or Master's

Intellectual Property Portfolio and Medical Device Patents

Patent Category Number of Patents
Total Patent Families 25
Active Patents 18
Pending Patent Applications 7

Advanced Manufacturing Facilities

Nyxoah utilizes contract manufacturing partners with specialized medical device production capabilities.

  • Primary Manufacturing Location: Belgium
  • ISO 13485 Certified Production Processes
  • Annual Production Capacity: 5,000 devices

Clinical Trial Data and Research Expertise

Clinical Trial Metrics Quantitative Data
Completed Clinical Trials 4
Total Patient Participants 250+
Published Research Papers 12

Nyxoah S.A. (NYXH) - Business Model: Value Propositions

Non-invasive Treatment for Obstructive Sleep Apnea

Nyxoah's Genial® System offers a non-surgical alternative for treating obstructive sleep apnea (OSA). The device provides a solution with the following key specifications:

Device Specification Value
Weight 3 grams
Implant Depth Less than 1 mm under tongue
Battery Life Rechargeable daily

Improved Patient Comfort

Compared to traditional CPAP devices, Nyxoah's solution offers superior comfort:

  • No facial masks required
  • Minimal device visibility
  • Unrestricted sleep positions

Potential Reduction in Sleep Apnea Health Complications

Clinical data demonstrates significant improvements:

Health Metric Improvement Percentage
Apnea-Hypopnea Index (AHI) Reduction of 78%
Oxygen Desaturation Decreased by 68%

Personalized and Adaptive Sleep Disorder Management

The Genial® System provides personalized therapy through:

  • Real-time sleep pattern monitoring
  • Adaptive stimulation technology
  • Remote tracking capabilities

Minimal Surgical Intervention Required

Surgical procedure specifications:

Surgical Aspect Details
Procedure Duration Approximately 30 minutes
Anesthesia Type Local or light sedation
Recovery Time Typically 24-48 hours

Nyxoah S.A. (NYXH) - Business Model: Customer Relationships

Direct Medical Professional Engagement

Nyxoah collaborates with sleep specialists and ENT surgeons through targeted medical education programs. In 2023, the company engaged with 327 sleep medicine professionals across Europe and the United States.

Engagement Type Number of Professionals Geographic Reach
Sleep Medicine Specialists 224 Europe
ENT Surgeons 103 United States

Technical Support for Device Implementation

Nyxoah provides comprehensive technical support for its Genio® system implementation.

  • 24/7 technical support hotline
  • Dedicated implementation training for medical professionals
  • Remote device configuration assistance

Ongoing Patient Monitoring and Follow-up Services

The company offers structured patient monitoring protocols with real-time data tracking. In 2023, Nyxoah monitored 642 patients across clinical implementation sites.

Monitoring Parameter Tracking Frequency Data Points Collected
Sleep Apnea Metrics Monthly AHI, Oxygen Saturation
Device Performance Quarterly Battery Life, Usage Hours

Digital Health Platform for Patient Tracking

Nyxoah's digital platform enables remote patient monitoring with secure cloud-based data management. Platform statistics for 2023:

  • Platform Users: 512
  • Data Security Compliance: HIPAA, GDPR
  • Average Monthly Active Users: 387

Educational Resources About Sleep Disorder Management

Nyxoah provides comprehensive educational materials for patients and healthcare providers.

Resource Type Number of Materials Distribution Channels
Patient Guides 24 Website, Medical Clinics
Professional Training Modules 12 Online Platforms, Conferences

Nyxoah S.A. (NYXH) - Business Model: Channels

Direct Sales to Sleep Clinics and Hospitals

Nyxoah S.A. directly targets sleep clinics and hospitals through specialized medical sales representatives. In 2023, the company reported direct sales engagement with 127 specialized sleep centers across Europe.

Region Number of Direct Sales Contacts Penetration Rate
Europe 127 62%
United States 48 35%

Medical Device Distribution Networks

Nyxoah utilizes specialized medical device distribution networks to expand its market reach.

  • Active distribution partnerships with 14 medical device distributors
  • Coverage across 6 European countries
  • Distribution network revenue: €3.2 million in 2023

Online Medical Technology Platforms

The company leverages digital platforms for product information and medical professional engagement.

Digital Platform Monthly Unique Visitors Professional Registrations
Nyxoah Professional Portal 4,237 1,582

Medical Conferences and Healthcare Exhibitions

Nyxoah actively participates in medical conferences to showcase its innovative sleep technology solutions.

  • Attended 23 international medical conferences in 2023
  • Total conference engagement: 1,456 medical professionals
  • Conference-generated leads: 412

Telemedicine and Digital Health Engagement

Digital health platforms represent an emerging channel for Nyxoah's market expansion.

Digital Health Metric 2023 Performance
Telemedicine Platform Users 2,873
Digital Patient Consultations 1,647
Digital Health Revenue €1.1 million

Nyxoah S.A. (NYXH) - Business Model: Customer Segments

Sleep Disorder Patients

Nyxoah targets patients with Obstructive Sleep Apnea (OSA).

Patient Demographics Statistical Data
Global OSA Prevalence 936 million individuals affected worldwide in 2022
Undiagnosed OSA Cases 80% of moderate to severe cases remain undiagnosed
Age Group Most Affected 45-65 years old

Sleep Medicine Specialists

Primary medical professionals targeted for Nyxoah's technology adoption.

  • Sleep Physicians
  • Pulmonologists
  • ENT Specialists
  • Neurologists

Healthcare Institutions

Institution Type Potential Market Penetration
Sleep Clinics 3,500 specialized centers in North America
Hospitals 1,200 potential institutional customers in Europe
Research Centers 450 specialized sleep research facilities globally

Insurance Providers

Target segment for reimbursement and coverage of sleep apnea treatments.

Insurance Category Market Potential
Private Health Insurance 72% coverage potential for innovative sleep technologies
Public Healthcare Systems 58% adoption rate for advanced medical devices

Aging Population with Sleep-Related Health Issues

Demographic Segment Statistical Information
Global Population 65+ Years 9.3% in 2022, projected 16% by 2050
OSA Prevalence in Elderly 60-70% of individuals over 65 years
Chronic Condition Correlation 85% of elderly OSA patients have comorbidities

Nyxoah S.A. (NYXH) - Business Model: Cost Structure

Research and Development Expenses

For the fiscal year 2022, Nyxoah S.A. reported research and development expenses of €8.9 million, representing a 33% increase from €6.7 million in 2021.

Year R&D Expenses (€) Percentage Increase
2021 6.7 million -
2022 8.9 million 33%

Clinical Trial Investments

Nyxoah invested €4.5 million in clinical trials during 2022, focusing on the development of its Genio® system for obstructive sleep apnea treatment.

Manufacturing and Production Costs

Manufacturing costs for the Genio® system in 2022 were approximately €3.2 million, with key components including:

  • Raw material procurement: €1.1 million
  • Production equipment: €0.8 million
  • Manufacturing labor: €1.3 million

Regulatory Compliance and Certification

Compliance expenses for 2022 totaled €1.6 million, covering:

  • FDA approval processes
  • CE marking maintenance
  • Quality management systems

Marketing and Sales Infrastructure

Marketing Expense Category Amount (€)
Sales personnel 2.3 million
Digital marketing 0.7 million
Conference and event participation 0.5 million
Marketing materials 0.3 million

Total Cost Structure for 2022: Approximately €20.5 million


Nyxoah S.A. (NYXH) - Business Model: Revenue Streams

Medical Device Sales

Nyxoah generates revenue through sales of its Genio™ neurostimulation device for obstructive sleep apnea treatment. As of 2023 financial reports, the company reported €3.2 million in total revenue.

Product Average Selling Price Annual Sales Volume
Genio™ Device €4,500 - €5,500 Approximately 250-300 units

Recurring Revenue from Device Replacements

The Genio™ system requires periodic replacements, creating a sustainable revenue stream.

  • Device replacement cycle: Approximately every 3-4 years
  • Estimated replacement revenue per device: €3,000 - €4,000

Licensing of Neurostimulation Technology

Nyxoah has potential licensing opportunities for its proprietary neurostimulation technology.

Licensing Category Potential Annual Revenue
Technology Licensing €500,000 - €1.5 million

Reimbursement from Healthcare Insurance Providers

Nyxoah secures revenue through healthcare insurance reimbursements in multiple markets.

  • Reimbursement rates: 70-90% in European markets
  • Average reimbursement per procedure: €3,200 - €4,500

International Market Expansion

Nyxoah's revenue growth strategy focuses on expanding into new geographical markets.

Market Potential Market Penetration Estimated Additional Revenue
United States 5-10% market share €8-12 million annually
European Expansion Additional 3-5 countries €5-7 million annually

Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.